arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Clene Inc.

CLNN
$5.37 ▲ +0.05 (+0.94%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
27 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
78
Health
Good
Bullish
auto_awesome

Analytical Summary

Clene Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $62.5M
Dividend Yield
Revenue Growth -81.5%
Op. Margin
ROIC 185.5%
FCF / Share $-0.39
Trailing P/E
Price / Book
FCF Yield
Debt / Equity -0.94
info Valuation on last close. End-of-day price, Aug 7, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$15.00K
↓ -81.5%
Net Income Profit after all expenses
$-8.09M
↓ -977.4%
FCF / Share Free cash flow per share
$-0.39
↑ +31.5%
Long-Term Debt Long-term obligations
$17.70M
↓ -0.5%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns
100
Financial Health
66
Cash Quality
49

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 27 quarters